Qyuns Therapeutics Announces Major Developments: Caldera Therapeutics Merger, \$278 Million Financing, and Proposed Nasdaq Listing
Key Highlights
- Caldera Therapeutics and Synlogic to Merge: Caldera Therapeutics, a key partner of Qyuns Therapeutics, will merge with Synlogic, Inc. in an all-stock transaction, forming a new holding company expected to be listed on the Nasdaq Capital Market under the ticker symbol “CALD”.
- Significant \$278 Million Private Placement: Caldera has secured commitments for an upsized private placement raising approximately \$278 million from leading healthcare investors and mutual funds.
- Qyuns Therapeutics’ Stake: Qyuns Therapeutics’ equity interest in Caldera Therapeutics is approximately 11.48% after dilution from previous financing rounds.
- QX030N/CLD-423 Clinical Progress: The lead asset, a first-in-class bispecific antibody for IBD, is advancing through clinical trials with promising early safety and pharmacokinetic results.
- Potential Impact on Shareholders: These developments could significantly affect Qyuns Therapeutics’ valuation, future revenues, and strategic positioning in the biotech sector.
Detailed Overview
1. Caldera Therapeutics and Synlogic Merger
On July 29, 2026, Caldera Therapeutics, Inc.—the exclusive global licensee of Qyuns Therapeutics’ investigational drug QX030N/CLD-423—entered into a definitive merger agreement with Synlogic, Inc. The merger will be executed as an all-stock transaction, resulting in both companies becoming wholly owned subsidiaries of a newly formed holding company. Upon completion, the combined entity will operate under “Caldera Therapeutics, Inc.” and is expected to be listed on the Nasdaq Capital Market, trading under the symbol “CALD”.
The post-merger shareholding structure is expected to be:
- Pre-merger Synlogic shareholders: ~2.3%
- Pre-merger Caldera Therapeutics shareholders: ~62.8%
- Investors from the concurrent private placement: ~34.9%
The exact percentage for Synlogic shareholders may adjust based on Synlogic’s net cash position at closing.
2. \$278 Million Private Placement Financing
To support the merger and the advancement of QX030N/CLD-423, Caldera Therapeutics has secured commitments for an upsized private placement of approximately \$278 million. The financing is fully committed by an impressive syndicate of well-known healthcare institutional investors and mutual funds, including Bain Capital Life Sciences, TCGX, Atlas Venture, venBio Partners, Omega Funds, Blackstone Multi-Asset Investing, LAV, Wellington Management, Janus Henderson Investors, Sirenia Capital Management LP, Vivo Capital, and several others.
This substantial capital injection will fund the Phase II clinical development of QX030N/CLD-423 for ulcerative colitis and Crohn’s disease, as well as potential expansion into other immune-mediated diseases. The private placement is set to close concurrently with the merger, subject to customary closing conditions.
Importantly, Qyuns Therapeutics did not participate in the private placement and has not provided any financial accommodation or guarantee for the transaction. The financing was completed solely by Caldera Therapeutics.
3. Qyuns Therapeutics’ Stake in Caldera Therapeutics
Qyuns Therapeutics originally acquired a 24.88% stake in Caldera Therapeutics via a share purchase agreement completed on May 14, 2025. However, following Caldera’s Series A-1 financing, Qyuns’ stake was diluted to approximately 11.48% as of June 30, 2026. This equity position means Qyuns stands to benefit from Caldera’s future value creation but with a reduced share of upside relative to its initial investment.
4. QX030N/CLD-423 – Clinical Update
QX030N/CLD-423 is an innovative bispecific antibody targeting both TL1A and IL-23p19 pathways, designed for the treatment of inflammatory bowel disease (IBD) and other immune-mediated diseases. By combining these two mechanisms, the molecule aims to surpass the efficacy of single-target therapies.
The molecule incorporates a natural IgG structure and a monovalent 1+1 format to lower immunogenicity and includes a half-life extension mutation (YTE) for improved dosing convenience. Current Phase I data from a healthy volunteer trial in Australia indicate:
- Favorable tolerability and safety with no dose-limiting toxicities across four single ascending dose cohorts
- Pharmacokinetics supportive of once every 8 or 12 weeks dosing in IBD patients
- Rapid and sustained target engagement
- Low incidence of anti-drug antibodies, suggesting a positive immunogenicity profile compared to bivalent anti-TL1A antibodies
Further data from additional cohorts and multiple-dose groups are expected later in 2026.
5. Governance and Leadership Post-Merger
Upon closing, the combined company will be led by Dr. Praveen Tipirneni, Caldera’s current CEO. The board of directors will be composed of Caldera’s current board, providing continuity in leadership and strategic direction.
Potential Shareholder Impact and Price Sensitivity
- The merger, Nasdaq listing, and substantial financing are highly material and could positively impact Qyuns Therapeutics’ valuation due to:
- Increased visibility and credibility for its partner asset
- Acceleration of clinical programs with robust funding
- Potential for future revenue streams via its equity stake in Caldera
- However, dilution of Qyuns’ equity stake and the fact that it did not participate in the new financing mean its influence and potential returns are less than originally anticipated.
- Investors should closely monitor further clinical results, regulatory progress, and the final terms of the merger, as these will determine the ultimate value realization for Qyuns shareholders.
Conclusion
Overall, this announcement represents a major strategic milestone for Qyuns Therapeutics and its partner Caldera Therapeutics. The combination of a high-profile merger, significant new capital, and progress of a potentially first-in-class IBD therapy could have a meaningful impact on Qyuns’ share price and future outlook. Shareholders and potential investors are advised to exercise caution and stay informed as these developments progress.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult professional advisors before making investment decisions. The information provided is based on company announcements as of July 29, 2026, and may be subject to change.
粵語版
Qyuns Therapeutics 宣佈重大發展：Caldera Therapeutics 合併、2.78億美元融資及納斯達克上市計劃
重點摘要
- Caldera Therapeutics 與 Synlogic 合併： Qyuns Therapeutics 之合作夥伴 Caldera Therapeutics 將與 Synlogic, Inc. 全股本合併，成立新控股公司，預期於納斯達克資本市場以「CALD」為代號上市。
- 2.78億美元私募融資： Caldera 獲多家頂尖醫療機構及基金承諾，成功籌集約2.78億美元資金。
- Qyuns Therapeutics 持股： Qyuns 於 Caldera Therapeutics 的股權經稀釋後約為11.48%。
- QX030N/CLD-423 臨床進展： 重點資產雙特異性抗體於臨床試驗階段，早期安全性及藥代數據理想。
- 對股東潛在影響： 相關消息或顯著影響公司估值、未來收入及生物科技行業戰略地位。
詳盡內容
1. Caldera Therapeutics 與 Synlogic 合併
2026年7月29日，Caldera Therapeutics（Qyuns 主要合作夥伴及QX030N/CLD-423全球唯一授權方）與 Synlogic, Inc. 達成合併協議。合併後成立的新控股公司將會在納斯達克資本市場以「CALD」代號上市。
合併後股權分佈預期如下：
- 合併前 Synlogic 股東：約2.3%
- 合併前 Caldera 股東：約62.8%
- 私募融資投資者：約34.9%
最終分佈或因 Synlogic 合併前現金水平有所調整。
2. 2.78億美元私募融資
Caldera 為支持合併及推進QX030N/CLD-423，已獲眾多頂尖醫療基金如 Bain Capital Life Sciences、TCGX、Atlas Venture、venBio Partners、Omega Funds、Blackstone、多家共同基金等認購2.78億美元。資金將用於推動QX030N/CLD-423 於潰瘍性結腸炎及克隆氏症第二期臨床及其他免疫相關疾病開發。
值得注意，Qyuns 並無參與此次私募，亦無提供任何財務擔保或融資，所有資金均由 Caldera 單獨完成。
3. Qyuns Therapeutics 持股狀況
Qyuns 於2025年5月14日完成收購 Caldera 24.88%股權。但經A-1輪融資稀釋，至2026年6月30日持股降至約11.48%，未來將以此比例分享 Caldera 成果。
4. QX030N/CLD-423 臨床進展
QX030N/CLD-423 屬雙特異性抗體，針對TL1A及IL-23p19通路，用於治療炎症性腸病及免疫疾病。產品設計降低免疫原性，並具備長效半衰期，利於8至12週維持劑量注射。
澳洲進行的第一期健康志願者臨床試驗顯示：
- 安全耐受性佳，無劑量限制毒性
- 藥代動力學理想，支持長效維持注射
- 快速並持續阻斷目標通路
- 低抗藥抗體產生，免疫原性表現佳
更多多劑量組數據將於2026年內公布。
5. 合併後管理層
合併完成後，公司將由Caldera現任CEO Dr. Praveen Tipirneni 領導，董事局由 Caldera 現屆董事組成。
對股東潛在影響及股價敏感事項
- 合併、納斯達克上市及大額融資均屬重大利好，有望提升 Qyuns 估值及行業地位。
- 不過，Qyuns 持股被稀釋及未參與新一輪融資，未來分成比例較原始投資下降。
- 建議投資者密切關注臨床進展、監管情況及合併細節，這些都將直接影響公司股價及前景。
結語
總括而言，是次公告為 Qyuns Therapeutics 及其夥伴 Caldera Therapeutics 重大里程碑。合併、龐大融資及創新藥物臨床進展均屬潛在股價敏感消息，投資者宜審慎留意進一步發展。
免責聲明： 本文僅供參考，並不構成任何投資建議。投資者應自行研究並諮詢專業意見。本文所載資料截至2026年7月29日，如有更改恕不另行通知。
